Publication | Open Access
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
41
Citations
28
References
2022
Year
AstraZeneca and the UK Department of Health and Social Care through the UK National Institute for Health and Care Research.
| Year | Citations | |
|---|---|---|
Page 1
Page 1